Compugen (CGEN) has released an update.
Compugen Ltd. is set to receive a $5 million milestone payment from AstraZeneca following the first patient dosing in a Phase 3 trial of rilvegostomig for non-small cell lung cancer. The trial will assess the effectiveness of rilvegostomig alone and in combination with other therapies across multiple countries. This development marks a significant step in Compugen’s strategy to broaden the potential of its pipeline through partnerships and could lead to future milestone payments and royalties.
For further insights into CGEN stock, check out TipRanks’ Stock Analysis page.
